Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARNI in HFpEF Cardiac Fibrosis
NCT05089539Phase 2Unknown
- Sponsor
- Chongqing Medical University
- Start
- Nov 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sacubitril + valsartan in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Chongqing Medical University. Primary endpoint: Extracellular volume at 3 months. Status: unknown.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT05089539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089539.